Xcout Intel
Carmine Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Carmine Therapeutics, Inc. among biotechnology companies — ranked by similarity to what Carmine Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Carmine Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Carmine Therapeutics, Inc.
Carmine Therapeutics, Inc. is an EVX Ventures company headquartered in Cambridge, Massachusetts, focused on developing novel gene therapies.
Carmine Therapeutics, Inc. at a glance
Carmine Therapeutics, Inc. is a biotechnology company headquartered in United States. It has raised at least $17.1M across the 3 funding rounds on record, 2 of them with a disclosed amount. Its most recent funding round, Series A, closed in October 2022. Xcout tracks 4 named people at Carmine Therapeutics, Inc., including Tenzin Gocha, Ph.D. (President).
Carmine Therapeutics, Inc. leadership
- Tenzin Gocha, Ph.D.President
- XQ LinCo-Founder & Chairman
- Prof. Harvey LodishScientific Co-Founder & Board Member
- Elan EzicksonDirector
Carmine Therapeutics, Inc. funding rounds
At least $17.1M raised across the 3 rounds on record (2 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | Undisclosed | — | |
| SEC Form D filing | $13.7M | — | |
| — | $3.4M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Carmine Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Carmine Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Verve Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, dedicated to pioneering single-course gene editing medicines for cardiovascular disease.
Similar biotechnology company
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Similar biotechnology company
Exsilio Therapeutics Inc. is a biotechnology company headquartered in Boston, Massachusetts, founded in 2022 to pioneer genomic medicines and advanced genetic therapies.
Similar biotechnology company
Kelonia Therapeutics, Inc. is a clinical-stage biotech company headquartered in Boston, Massachusetts, focused on delivering genetic medicine for patients.
Similar biotechnology company
SparingVision is a genomic and gene therapy medicines company translating pioneering science into vision-saving treatments, with US headquarters located in Boston, Massachusetts.
Biotech
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Biotech
CPTx is a genetic medicines company that develops in vivo CAR-T therapies for cancer treatment. The company utilizes a proprietary single-stranded DNA (ssDNA) platform combined with lipid nanoparticle delivery systems to create scalable, non-viral genetic therapies.
Biotech
Nuevocor is a biotechnology research company with its headquarters located in Singapore and additional operations in the United States and France. The company focuses on developing breakthrough gene therapies to treat untreatable cardiomyopathies.
Similar biotechnology company
Averna Therapeutics is a biotechnology company developing genomic medicines utilizing RNA and lipid nanoparticle technologies. The company focuses on safe and efficient gene insertion and the treatment of rare genetic diseases through research and development teams located in Boston and Israel.
Similar biotechnology company
NextPoint Therapeutics is a private biopharmaceutical and technology company based in Cambridge, Massachusetts, focused on expanding novel therapeutic possibilities.
Biotech
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Biotech
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Carmine Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Carmine Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →